Ozempic, Wegovy and Zepbound Cost per Pound Lost

GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound, and their compounded equivalents — have changed what is possible in obesity medicine. The clinical trial loss figures are real: 15% average weight loss on Wegovy, 20% on Zepbound, with a meaningful fraction of users clearing 25%. The cost is also real. A year of Wegovy at cash price is more than $16,000. A year of Zepbound is closer to $12,700. Insurance covers some of this bill for some people. Nobody pays list price for long, but nobody pays nothing either.

This calculator does three things. It projects expected weight loss at your starting weight and duration using the published trial efficacy curves. It calculates the cash cost and your out-of-pocket after insurance coverage. And it returns a cost-per-pound-lost figure that lets you compare drugs apples-to-apples. GLP-1s are a genuine medical breakthrough, but they are also the single largest financial commitment most adults will make around their body weight, and both sides of that equation deserve real numbers.

How the drugs work

GLP-1 (glucagon-like peptide-1) is a gut hormone your body releases when you eat. It signals the pancreas to release insulin, slows gastric emptying (food stays in the stomach longer), and acts on appetite centers in the brain to reduce hunger. The synthetic versions — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are analogs of these natural hormones with extended half-lives that allow once-weekly dosing. Tirzepatide is a dual GLP-1 and GIP agonist, which is why it produces somewhat greater weight loss than pure GLP-1 agonists.

The mechanism is primarily appetite suppression. Users report reduced food noise (intrusive thoughts about food), earlier satiety, and lower interest in high-calorie foods. The medication does not 'burn' calories; it makes eating less feel less aversive. Weight loss still results from a caloric deficit.

Brand costs in 2026

Wegovy (semaglutide 2.4mg weekly) lists at roughly $1,350 per month cash. Zepbound (tirzepatide) lists at $1,060. Mounjaro (tirzepatide indicated for type 2 diabetes but widely prescribed off-label for obesity) is similar. Ozempic (semaglutide 0.5–2mg weekly for diabetes) runs $970 per month. The manufacturers (Novo Nordisk and Eli Lilly) offer savings programs for eligible patients that can bring the out-of-pocket monthly cost to $25–650 depending on insurance status.

Direct-to-consumer programs from LillyDirect, Ro, Calibrate, Sequence, and WeightWatchers Clinic offer Zepbound vials (self-injected from a vial rather than the proprietary pen) at approximately $499 per month for the 2.5mg and 5mg doses. This has been the single biggest 2025–2026 shift in GLP-1 pricing and is worth pricing against compounded alternatives before committing to a course.

Compounded alternatives

During the 2022–2024 drug shortage, compounding pharmacies were legally allowed to produce semaglutide and tirzepatide at $200–500 per month — a fraction of brand-name cost. As of late 2024, the FDA declared the shortage resolved for both drugs and ordered most large compounders to wind down production. Some small-scale personalized compounding remains legal when specific patient factors justify it, and offshore pharmacies continue to operate in a gray zone.

If you are pricing compounded alternatives, verify the pharmacy is state-licensed and accredited by the PCAB or equivalent, confirm the source of the active pharmaceutical ingredient, and get your first few injections under a telehealth physician's monitoring. Counterfeit and under-dosed compounded product has been found in seizure studies, and the efficacy you see in trials depends on receiving the correct dose.

Cost per pound lost — the right comparison

At list prices without insurance, Wegovy at $1,350/month × 12 months ÷ approximately 30 pounds lost on a 200-pound patient = $540 per pound. Zepbound is cheaper per pound ($310 at 200 lb × 20.5% loss). Compounded semaglutide lands around $60–100 per pound. Insurance coverage of 50–80% changes this math dramatically and can bring brand-name cost per pound below $100, which competes with supervised diet programs.

For comparison, bariatric surgery (sleeve gastrectomy or gastric bypass) typically produces 25–30% weight loss at a one-time cost of $15,000–25,000, or roughly $200–400 per pound over a lifetime of maintained loss. A good medically supervised diet program (registered dietitian plus structured exercise) costs $2,000–5,000 over 12 months and produces 5–10% loss for adherent patients — cheaper per month but smaller results. GLP-1 results scale with affordability.

Who should consider a GLP-1

The FDA-approved indications are BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, dyslipidemia). Most insurance plans that cover GLP-1s require documentation of at least one previous supervised weight-loss attempt and a current BMI that meets criteria.

Outside the approved indications, the risk-benefit calculation gets harder. For an adult with BMI 26 trying to lose 15 pounds of vanity weight, GLP-1 side effects and long-term lean mass implications rarely justify the cost, and sustained lifestyle change has similar outcomes at this weight range. For adults with BMI 30+ and failed prior diet attempts, the medication changes the calculation fundamentally — adherence to a deficit becomes possible when hunger is pharmacologically managed.

Lean mass preservation on GLP-1s

The single most important GLP-1 optimization is protecting lean body mass. Trials show 25–40% of total weight loss on semaglutide comes from lean mass — a higher proportion than diet-and-exercise loss, where the well-trained dieter loses 5–15% as lean mass. The reason is simple: GLP-1 users eat less than they would on diet alone, and if they eat less without deliberately maintaining protein and strength training, they lose more muscle.

The fix is non-negotiable: 0.8 to 1 gram of protein per pound of lean body mass (use the lean body mass calculator to find your number), and three resistance training sessions per week. Users who hit both retain 80%+ of lean mass during GLP-1 weight loss. Users who hit neither lose muscle at the same rate as a crash dieter.

Stopping and rebound

Current consensus is that GLP-1 therapy is long-term. STEP-4 showed two-thirds of lost weight returns within a year of stopping. The hormonal effects that suppressed appetite reverse within weeks, and the body's leptin-driven hunger response returns. Plan the financial commitment as a 3–5 year floor, not a 6–12 month sprint.

If cost forces a stop, the smoothest off-ramp is a slow dose taper combined with a reverse diet to increase caloric intake without immediate rebound, aggressive resistance training to preserve muscle, and high-protein intake maintained from the cut phase. Pair the exit with the plateau calculator in case weight creeps up despite effort.

What this calculator will not tell you

The numbers here are population means applied to your inputs. Individual response varies widely. About 15% of GLP-1 users are 'super-responders' who lose 25%+ even on Wegovy; another 15% are 'non-responders' who lose less than 5% after six months. If you are in the latter group, your physician will typically discuss switching agents (semaglutide to tirzepatide or vice versa) or stopping.

For the full picture, run this calculator alongside the calorie deficit tool to understand the diet piece GLP-1s augment rather than replace, and the safe fat loss rate tool to sanity-check that the trial loss pace fits your body.